Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group
about
Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology GroupTargeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectivesBeyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute LeukemiaRevisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemiaSelective Inhibitors of Histone Methyltransferase DOT1L: Design, Synthesis, and Crystallographic StudiesPotent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemiaModifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407High-risk childhood acute lymphoblastic leukemiaOutcomes for children and adolescents with cancer: challenges for the twenty-first century.Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyMLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemiaThe molecular mechanics of mixed lineage leukemia.High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology GroupCytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements.Demographic and prognostic factors of 455 patients with acute leukemia admitted to two referral hospitals in tehran-iran during ten years (2001-2011).Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemiamll ortholog containing functional domains of human MLL is expressed throughout the zebrafish lifespan and in haematopoietic tissuesEffective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.Treatment of pediatric acute lymphoblastic leukemia.Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyondCCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1LTreatment of infant leukemias: challenge and promise.3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L.Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group.Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia.Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3)An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias.The molecular biology of mixed lineage leukemia.Molecular pathology of mixed-lineage leukemia.
P2860
Q24657000-022B99BE-7F61-41EB-8D81-C870ED8949DAQ26744441-360EF3E0-EA24-4E44-87D5-55F5E13BDE47Q26781328-8630DF0C-F10C-4C7A-A914-78BAF6E125A1Q26783577-3C9EA783-D820-41EA-81AE-0FCBA98CDF39Q27674356-CAC13DD6-DEEB-4905-8233-0E99C349E339Q30538418-031D8F0D-06E5-4D94-B106-A19A0A1B473EQ33559419-84B1D1E3-7334-491D-BE33-715F99C8CDD6Q33622837-0C020078-316B-404F-A871-797BA25CB2DBQ33897659-B31ADEB1-8D62-4E3A-8883-541D0A498151Q34003323-205663F2-2B3E-452D-8A73-E8AE71F66FC8Q34031153-74733ED2-1D60-401D-AEF3-54008F4703C4Q34046263-72556C4A-7E94-4A49-8791-4308A91A7BB4Q34060270-05299726-D0BC-407F-953A-51F55335E45CQ34165735-21208D2A-0B18-4F1D-BF0A-396AF0C0B1AFQ34516051-71476176-EC89-4441-8A94-66A1E0A4DD64Q34645259-121A0E16-609B-4E3C-BFB1-63EAF97E0447Q34679190-FCA747E4-878C-4778-A2B5-401EDBD881B8Q34845478-3B9CD9B2-694C-49ED-8664-27E65A09B59AQ34959094-34E58E75-45F6-41D8-BEDE-A58F8F1FD12AQ35056301-DA9DDFEC-DC1C-40C5-962F-192E63A04031Q35172438-631B4A4A-A63D-411D-9A1F-5A53EBA1238BQ35178411-4665ECB6-BE4E-4FD5-8ADA-E7EF0EE38A88Q35196702-3D4DF96F-C2A0-4F6B-897D-F3723F9A6C90Q35591430-AED69EF7-992E-45E8-8295-CF27EADA55CFQ35634908-1CBCCC43-C248-468A-9768-1269B72C850EQ35781265-9F302D00-7FA1-4096-AFC0-530819B5C5F9Q35802220-4E95EE2F-8EA6-4632-8DBE-5E25D9675ED7Q35967446-A5B667F2-6667-4AA8-A889-24258D3FF5C5Q36056038-C6C63E75-9740-4668-B33F-6711EDDBF378Q36330013-9B6E7FD9-9B50-4E6B-9C67-23E18C8D6290Q36508988-F1F01AEF-9830-47FF-A0B2-D4B1300E767EQ36930863-5702C705-0F3F-4FC2-B263-C3774F66557EQ36940199-362A8CA9-CC3A-4074-9D41-09F105B3FEB5Q37166872-AF4AA8B9-916E-4C0C-AA67-0C1CDA481368Q37273166-1C40A8B6-075E-4C18-ABAA-7200A232E117Q37317957-75868A47-E8FB-4814-9140-B74E172A4596Q37486133-BF95610E-1B3E-4F77-9725-C22470C9ABF5Q37519680-021CDED9-61AB-47C1-8D08-1955AC9BA60CQ37522825-1F261DB8-EA4B-422A-AD8C-345DEFE38D56Q37620396-C7051432-3CBA-4E71-8488-C24A92674562
P2860
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Analysis of prognostic factors ...... the Children's Oncology Group
@ast
Analysis of prognostic factors ...... the Children's Oncology Group
@en
type
label
Analysis of prognostic factors ...... the Children's Oncology Group
@ast
Analysis of prognostic factors ...... the Children's Oncology Group
@en
prefLabel
Analysis of prognostic factors ...... the Children's Oncology Group
@ast
Analysis of prognostic factors ...... the Children's Oncology Group
@en
P2093
P2860
P1433
P1476
Analysis of prognostic factors ...... the Children's Oncology Group
@en
P2093
Children's Oncology Group
Doojduen Villaluna
Franklin O Smith
Gregory H Reaman
Harland Sather
Helen S Johnstone
Joanne M Hilden
Patricia A Dinndorf
Ron McGlennen
Sharon O Meerbaum
P2860
P304
P356
10.1182/BLOOD-2005-07-3011
P407
P577
2006-03-23T00:00:00Z